Setting-30 general practices in 15 English counties.
Subjects-600 dependent heavy smokers (>, 15 cigarettes daily) who were well motivated to give up.
Interventions-Brief general practitioner advice, booklet, and 16 hours per day patch treatment for 18 weeks with brief support and follow up at one, three, six, 12 , 26, and 52 weeks.
Main outcome measures-Self reported complete abstinence for up to one year with biochemical validation at all follow up points.
Results-Nicotine patches reduced the severity of craving and adverse mood changes in the first weeks of withdrawal and doubled the rate of initial cessation at week 3 (nicotine group 36% of patients (144W 400), placebo group 16*5% of patients (33/200)) and of continuous abstinence throughout one year (nicotine group 9.3% (37), placebo group 5*0%/ (10)).
A dose increase at week 1 among patients experiencing difficulty in quitting increased the proportion who achieved abstinence at week 3. There were no adverse systemic effects attributable to nicotine, but the incidence of moderate or severe local irritation
Introduction
Cigarette smoking has long been recognised as the major single cause of preventable disease and premature death in developed countries.' According to estimates by Peto et al between a third and a half of smokers will die from smoking if they do not give it up. Those who die aged lose an average of23 years of life.2 Although many smokers succeed in stopping without any formal help or treatment, there are many more who fail despite trying hard to stop.
Nicotine replacement therapy with nicotine chewing gum is established as an effective aid to stopping smoking,3 4 and transdermal nicotine patches have recently become available for clinical use in several countries.5 A number of placebo controlled trials have shown that nicotine skin patches are effective at reducing craving for cigarettes and increasing the rates of short term cessation"O but only two, carried out at specialist clinics, have assessed and shown efficacy over a longer term." 12 It is important to evaluate the patches in general practice, where the efficacy of nicotine gum has been less consistent.41' A potential advantage of the skin patch is the ease of securing good compliance with minimal instruction. This makes it suitable for use as an adjunct to brief interventions targeted at many smokers. We report the outcome for up to one year of follow up of the first 600 subjects of a multicentre controlled trial in general practice.
Subjects and methods
The study was designed to evaluate the efficacy of nicotine skin patches (a) in alleviating withdrawal symptoms, (b) in enhancing initial cessation in the first three weeks of attempting to stop smoking, and (c) in preventing relapse in the first three months after stopping (weeks [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] and to examine the overall effect of these factors on increasing the rate of long term cessation for up to one year. Additional aims were to examine the effect of increasing patch nicotine dosage in those who seemed to respond inadequately to the standard dose and to compare the effects of gradual versus abrupt withdrawal of transdermal nicotine on the relapse rate after three months of abstinence from smoking. However, the size of the study sample was determined to address the four main questions and we were aware that statistical power might not be adequate for definitive answers to the two subsidiary points of interest.
The sample size of 1200 was planned to detect differences between the low rates of sustained abstinence expected after one year, and the study had a 95% chance to detect a difference of 10% versus 5% (p < 0 05, one sided test). Thus both a and I were set at 5%. This preliminary report of active and placebo differences in the first 600 subjects had 70% power to detect such a difference. A one sided test for outcome was regarded as appropriate in view of the consistent evidence from trials of higher success rates in the nicotine replacement condition. Again both subjects and their doctors or nurses were blind to whether the dose increase was real or placebo. Criteria for offering an extra patch were (a) self report of any lapse (even a puff) on the day ofthe week 1 visit or the preceding two days, (b) failure of carbon monoxide validation (s> 10 ppm), and (c) abstinent but having great difficulty with little confidence in being able to remain abstinent. This last criterion was left to the clinical judgment of the doctor or nurse. The dose increase option applied only to the week 1 visit, but once initiated it continued to the end oftreatment.
A further condition, randomised at entry, was a comparison of gradual versus abrupt withdrawal of transdermal nicotine over six weeks after week 12. A numbered package for each subject contained a full supply of the combination of patches necessary to complete the course, including weaning, but subjects were given supplies at each visit sufficient to last only until the next visit with patches for three days per week to spare. At entry to the study subjects were assigned to treatment according to a computer generated list compiled in blocks of six (four active, two placebo).
MEASURES AND PROCEDURES
One doctor in each practice served as investigator responsible for coordinating recruitment, treatment, and data collection. The protocol was flexible to enable doctors to recruit subjects opportunistically or from their computerised patient records. Likewise, the extent to which contact and brief support were provided by the doctors or delegated to their nurses could be varied to suit each practice. Although practice teams received no specific guidance on counselling smokers, a six page printed booklet (by MAHR) with information about the patch and how to give up smoking was BMJ VOLUME 306
given to each subject and served also to provide the practice teams with essential information.
At assessment (week 0) demographic data were recorded and subjects completed a smoking questionnaire which included measures of their dependence and motivation to stop.'5"6 At week 0 and all subsequent visits measures of expired air carbon monoxide concentration (Bedfont EC50 monitor), body weight, pulse, and blood pressure were taken, a saliva sample was collected for cotinine analysis, '7 Outcome-In the active treatment group 36% of patients (144/400) achieved initial cessation at week 3 compared with 16 .5% of patients (33/200) wearing placebo (X2=24-4; p<0-001), and 9.3% of patients in the active group (37) maintained complete abstinence up to one year compared with 5.0% of placebo treated subjects (10) (x2=3 34; p=0 034 ). This about doubling of the success rate was evident at all follow up points over the year (table II) . There was no evidence that active treatment reduced relapse during the treatment period between three weeks and three months, and about half the subjects in each group relapsed during the period. However, active treatment may have contributed to maintenance of the initial advantage gained in the first three weeks. Relapse rates after withdrawal of treatment after three months did not differ significantly in the active and placebo patch groups, nor was there evidence of an effect of abrupt versus gradual withdrawal oftransdermal nicotine. (11 6) slightly from baseline in the first few weeks. There was no evidence of greater sleep disturbance in patients on 81/392 (20 7) 28/197 (14-2) active treatment compared with those in the placebo (1-7)
10-4(1-7)
13-9 (1-3) (1-3) (15)). However, local irritation and itching at the patch sight were more common with the active patch. The incidences of moderate or severe effects in the active and placebo conditions were: local erythema 7 0% (27 cases) v 1.6% (three) (p < 0'0 1), urticaria or vesiculation 3 7% (14) v 1.6% (three) (p=0-19), oedema 2-1% (eight) v zero (p=0 06), and itching 16.4% (63) v 3-8% (seven) (p < 0 00 1). Active patches were discontinued in eight (2-0%) subjects on account of unwanted effects-skin reactions in six cases, pain in the patch bearing arm in one, and "intermittent blurred vision" in one. Patches were also withdrawn in three (1 -5%) placebo treated subjects (one for severe nausea, one for skin reaction, and one for severe lightheadedness and fainting). ' 
The main impact of the nicotine patch was to increase initial cessation during the first three weeks, and this effect was significantly enhanced by the dose increase among patients who had difficulty during the first week. The positive dose-response effect confirms findings of an earlier study in which the dose variation was not blind." There was no evidence that nicotine patch treatment reduced relapse after initial cessation, although it may have been necessary for maintaining the initial advantage gained. Among those who had stopped smoking at week 3, relapse rates were similar in the active and placebo treatment groups, about half the initial abstainers in each group relapsing by week 12. In general, success rates of interventions to help people stop smoking are related to the amount of face to face attention and support provided. As an adjunct to intensive clinic treatment the nicotine skin patch gave a net increase in success rate of 14% after six months (26% ofpatients given active treatment, 12% of patients given placebo) in one study." However, the amount of behavioural support entailed 45-60 minute group sessions weekly for six weeks and biweekly sessions for a further six weeks, as well as biweekly or monthly follow up visits from three to six months. General practitioners with a special interest who choose to provide more intensive support could expect to get similar results, but we have argued that most general practitioners could help more of their patients become ex-smokers by applying brief intervention to many smokers rather than intensive help for a few. '9 Brief advice together with a leaflet and warning of -follow up given opportunistically by general practitioners to all smokers who attend their surgeries has a net increase over non-intervention of 4-5% of patients who stop smoking and remain abstinent for one year.'9 However, those who respond to advice alone are mainly light smokers who average fewer than 10 cigarettes per day. The aim of our study was to target dependent heavy smokers to see whether use of nicotine patches as an adjunct to brief advice and support enables general practitioners effectively to help in these more difficult cases. Our sample of doctors came from a wide range of typical practices and received no special training. The net gain in success rate of 4-5% for active over placebo treatment at one year would be of enormous potential benefit if widely realised.
In conclusion, our results provide clear evidence that nicotine skin patches, used as an adjunct to brief advice and support in a general practice setting, are a safe and effective aid to stopping smoking in highly dependent but well motivated heavy smokers who are unlikely to succeed with advice and counselling alone. A dose increase in those having difficulty seems to enhance the rate of initial cessation. The 4-5% net gain over placebo treatment in long term cessation in heavy smokers offers scope for more effective targeting of intervention in primary care-that is, brief advice and support for light smokers, with the addition of nicotine patches for well motivated people who smoke over 10 cigarattes daily. Higher success rates might be obtained by doctors who give more intensive support, but we believe that more ex-smokers would be created by giving briefhelp to many smokers. 
RETROSPECT Ten years is a long time in general practice
This month marks the tenth anniversary of my north London practice, a time to take stock and realise what a lot of changes have been crammed into a brief decade. Some are for the better. I have not seen a case of measles for four years, although there were a dozen or so every year before the measles, mumps, and rubella vaccine. I also hope that the reason we have not seen a case of cervical carcinoma for five years may be that well over 80% of our women patients have smears every three years.
Other innovations appreciated by our patients are not of our making; keyhole surgery is expanding in so many fields that day surgery is becoming routine. Even some ectopic pregnancies can be treated without a laparotomy, and women with menorrhagia are offered hysteroscopic ablation instead of hysterectomy. Lasers can obliterate unsightly birthmarks, though not, in this cost limited world, tattoos. And on the medical side the outlook for patients with peptic ulcer, myocardial infarcts, and heart failure has been transformed by new drugs.
The practice population has changed a good deal too. Originally my senior partner and I had around 3000 patients. Now we have nearly 11000 patients, six partners, and a trainee. Until recendy our list was cosmopolitan but predominandy middle class. Then the council converted some large Edwardian houses into short stay accommodation and large numbers of refugees arrived. First 50 or so Tamils, 13 of whom memorably caught chicken pox within a month of their arrival. Then waves of Iranians, Kurds, Ethiopians, Somalis, and Sudanese.
It is families like these, arriving penniless in a strange country, who can benefit from a good health visitor or social worker. But funding for these services has been cut to the bone. We used to see a social worker regularly at our weekly practice meeting. But now they have become an endangered species, rarely sighted, and hard to track down. Our plans for an attached health visitor may come to nothing.
Many of the requirements of the general practice contract are a time consuming nuisance. Our expensive computer chums out reams of paper to prove that we are reaching our targets and, in an area of high mobility, our income is constantly threatened by the arrival of an unvaccinated child nearly 2 years old. We are sceptical of the value of regular health checks, though we have always invited new patients in for a consultation, as their notes still take around a year to reach us, even in this computerised age. But our existing patients with asthma or menopausal symptoms resist attempts to make them come in for special clinics. It is irritating that the new contract rewards the general practitioners who do well at easily measurable tasks of doubtful validity rather than the intangible art and science ofdoctoring.
But we have managed to live with the contract. Where we feel powerless is with the decline of the hospital services. We look back to the golden age of five years ago when a patient with an unusual condition could be referred to a teaching hospital in any part of London without benefit of an extracontractual referral. Waiting lists for outpatients used to be a maximum of two or three months, and there was never any difficulty in getting emergency admissions to our local hospital. How different it is now. Most urgent cases have to be referred through the Emergency Bed Service and some patients have ended up in hospitals several miles away.
We can see the appeal of fundholding as a way of regaining control, but we do not like the two tier system or relish the strain that organising our own budget would put on us and our excellent practice manager. Not so long ago we filled in our claim forms, sent them off to the family practitioner committee, and got on with our work in the hope and expectation that we would end up with a reasonable income. Now we have accounts on computer spread sheets and business plans. The future is not easy to plan when the goal posts are moved so frequently. We can only hope that there will be fewer changes in our second decade than our first.-MARGARET SAFRANER iS a general practitioner in London We welcome contributions to fillers: A patient who changed my practice; A paper that changed my practice; A memorable patient, The message I would most like to leave behind, or similar tQpics.
